🇺🇸 FDA
Patent

US 11254686

Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor

granted A61PA61P35/00

Quick answer

US patent 11254686 (Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor) held by Corvus Pharmaceuticals, Inc. expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corvus Pharmaceuticals, Inc.
Grant date
Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P35/00